title: Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy.
abstract: We investigated the prevalence of mixed cryoglobulinemia (MC) in 100 cases of chronic hepatitis C virus (HCV) infection and the effect of a 6-month treatment with interferon-alpha (IFN-alpha). Cryoglobulins were detected on admission in 36 of 100 patients and appeared during observation in a further 18 cases. Cryocrit ranged from 0.5% to 20%. Patients with MC were older and had a higher incidence of cirrhosis than those without MC. Immunologic characterization of the cryoprecipitate showed the presence of type II in 84% of cases and type III in 16%. The patients received IFN-alpha (6 MU three times per week) for 6 months. Fifty-seven were responders (i.e., reached normal aminotransferase levels), 26 of these relapsed within 2 months after IFN withdrawal, and 30 did not relapse. After IFN-alpha treatment, cryoglobulinemia disappeared in 11 of the 21 evaluable responders, but in none of the 15 nonresponder patients (p < 0.003). The clearance of MC was associated in all cases with clearance of HCV RNA. The delayed appearance of cryoglobulinemia in responders seems to be associated with a higher probability of relapse.
authors.affiliation: Institute of Medical Pathology, University of Verona, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Casaril
authors.forename: F
authors.initials: F
authors.lastname: Capra
authors.forename: G B
authors.initials: GB
authors.lastname: Gabrielli
authors.forename: A
authors.initials: A
authors.lastname: Bassi
authors.forename: S
authors.initials: S
authors.lastname: Squarzoni
authors.forename: R
authors.initials: R
authors.lastname: Dagradi
authors.forename: E
authors.initials: E
authors.lastname: De Maria
authors.forename: R
authors.initials: R
authors.lastname: Corrocher
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D003449:Cryoglobulinemia / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D003450:Cryoglobulins / Q000032:analysis; D005260:Female; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000628:therapy; D006521:Hepatitis, Chronic / Q000097:blood / Q000150:complications* / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011994:Recombinant Proteins
chemical_list: D000276:Adjuvants, Immunologic; D003450:Cryoglobulins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins